证券日报网讯 利民股份11月26日在互动平台回答投资者提问时表示，公司产品价格变动主要系供需关 系影响。公司杀菌剂如代森锰锌和百菌清等产品由于需求端旺盛，2025年产品价格持续上涨；阿维菌素 等产品在四季度处于淡季，需求下降导致价格下跌，后续价格预计会周期性反弹。对公司业绩的影响除 了考虑价格变动之外，还需考虑体量以及成本等多种因素。综合考虑价格、成本、体量等因素来看，代 森锰锌和百菌清对业绩的影响会更大。 （编辑 袁冠琳） ...

利民股份（002734.SZ）11月26日在投资者互动平台表示，公司产品价格变动主要系供需关系影响。公 司杀菌剂如代森锰锌和百菌清等产品由于需求端旺盛，2025年产品价格持续上涨；阿维菌素等产品在四 季度处于淡季，需求下降导致价格下跌，后续价格预计会周期性反弹。对公司业绩的影响除了考虑价格 变动之外，还需考虑体量以及成本等多种因素。综合考虑价格、成本、体量等因素来看，代森锰锌和百 菌清对业绩的影响会更大。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司拳头产品代森锰锌和百菌清，四季度价格同比大 涨。但阿维菌素等产品，同比环比均是下滑，请问对公司业绩影响，哪个更大？目前公司有哪些应对？ ...

利民股份（002734.SZ）11月26日在投资者互动平台表示，公司代森锰锌产能为45000吨/年，处于满产 满销状态；公司持有新河公司34%的股份，新河公司百菌清产能为30000吨/年，处于满产满销状态。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司拳头产品代森锰锌和百菌清，最新的产能是多 少？目前产能利用率怎么样？ ...

Group 1 - The core viewpoint of the report is that Limin Co., Ltd. (002734.SZ) is rated as "Buy" due to several positive factors influencing its performance [1] - The price increase of Manganese Zinc is expected to drive the company's performance growth [1] - The company's subsidiary, Deyanjichuang, has signed a cooperation agreement with BASF, indicating potential for future growth [1] - The company's proposed new energy project has passed the review, suggesting it may benefit from the increasing demand for new energy in the future [1]

Group 1: Macro Economic Insights - Construction activity is weakening, with the construction opening rate falling to historical lows, and industrial production remains at a historically high level [5][6] - Demand in the construction sector is weak, with low apparent demand for rebar and building materials, while automobile sales are also declining [5] - Recent weeks show a mixed performance in commodity prices, with black metals and coal prices recovering, while chemical products are experiencing a decline [6] Group 2: Industry Performance - The retail sales growth rate for October 2025 shows a year-on-year increase of 2.9%, but the growth rate continues to decline, particularly in the home appliance and automotive sectors [18][19] - The white liquor industry is in a bottoming phase, with structural recovery in demand during the holiday season, while the snack food sector shows resilience due to high-frequency demand [20] - In the poultry sector, chicken prices are supported by seasonal demand, while egg prices are declining, leading to accelerated culling of laying hens [22][23] Group 3: Company Updates - Li Min Co. (002734.SZ) has seen a price increase in its manganese-based products, and a strategic partnership with BASF has been established to enhance growth potential [37][38] - Bilibili (09626.HK) reported a significant increase in Q3 revenue, driven by advertising and new game launches, maintaining a "buy" rating [41][42] - Tencent Holdings (00700.HK) continues to experience high growth in revenue and net profit, with strong performance in both new and existing games, supported by AI applications [46][48] Group 4: Investment Opportunities - The 2025 private placement market is showing signs of recovery, with a significant increase in the number of new proposals and financing scale [10][12] - The Robotaxi industry is gaining traction, with companies like Xiaoma Zhixing and Wenyan Zhixing going public, indicating growth potential in the autonomous driving sector [31] - The outdoor camping and barbecue market is expected to thrive, with companies like Guoquan focusing on expanding their product offerings in this area [34]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The increase in the price of Mancozeb and the successful collaboration with BASF open up growth opportunities for the company [1][7] - The company has adjusted its profit forecasts for 2025-2027, expecting net profits of 560 million, 712 million, and 828 million yuan respectively, with corresponding EPS of 1.26, 1.60, and 1.86 yuan [6] - The company is well-positioned to benefit from the growing demand in the lithium battery sector due to its planned investment in new energy projects [8] Financial Summary - Revenue is projected to increase from 4,224 million yuan in 2023 to 5,699 million yuan in 2025, reflecting a year-on-year growth of 34.5% [9] - The net profit is expected to rise significantly from 62 million yuan in 2023 to 560 million yuan in 2025, indicating a year-on-year growth of 587.8% [9] - The gross margin is forecasted to improve from 17.0% in 2023 to 27.4% in 2025, while the net margin is expected to increase from 1.5% to 9.8% over the same period [9][12]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The company achieved significant year-on-year growth in performance, with revenue of 3.6 billion yuan in the first three quarters of 2025, up 7.6% year-on-year, and a net profit attributable to shareholders of 390 million yuan, up 661.7% year-on-year [4][12] - The growth is attributed to increased sales and prices of key products, improved gross margins, and increased investment income from affiliated companies [13] - The company is strategically positioning itself in AI and synthetic biology, with plans for the first fluorinated insecticide to be mass-produced in 2025 and collaborations to enhance pesticide development efficiency [14][15] Financial Performance Summary - For the first three quarters of 2025, the company reported revenue of 3.6 billion yuan, a net profit of 390 million yuan, and a non-recurring net profit of 380 million yuan, showing substantial increases of 7.6%, 661.7%, and 1014.9% respectively [4][12] - In Q3 2025, revenue was 1.15 billion yuan, up 9.7% year-on-year but down 7.6% quarter-on-quarter, with a net profit of 120 million yuan, reflecting a year-on-year increase of 522.3% but a quarter-on-quarter decrease of 24.6% [12][13] - The company expects revenue growth of 21%, 9%, and 8% for 2025, 2026, and 2027 respectively, with net profit growth of 528%, 12%, and 12% for the same years [15][16] Market Position and Strategy - The company is focusing on synthetic biology and AI applications to enhance its product development capabilities, which is expected to open new growth avenues [14][15] - The strategic partnership with Green Xin Nuo Bio aims to develop peptide-based biopesticides, indicating a move towards industrialization of synthetic biology strategies [14] - The company has also adjusted prices for key products in response to raw material cost increases and market demand, indicating proactive market strategies [13]

Macro Economic Overview - October exports are expected to remain resilient, with port throughput increasing by 8.9% year-on-year compared to 2024, indicating a potential export growth of approximately 1.9% [7] - Industrial production remains stable, with the manufacturing PMI falling to 49.0%, indicating a contraction in manufacturing activity, while the non-manufacturing PMI slightly improved to 50.1% [21][22] - Construction activity is weak, with building starts at historically low levels, while industrial operations are relatively strong, particularly in the chemical sector [4] Industry Performance - The media, coal, oil and petrochemical, steel, and banking sectors showed the highest gains in stock performance, with media leading at 3.125% [3] - Conversely, the non-ferrous metals, home appliances, automotive, and beauty care sectors experienced declines, with non-ferrous metals down by 1.210% [3] Real Estate Sector - New housing transactions have seen a significant year-on-year decline, with major cities reporting a 34% drop compared to 2023 and 2024 [6] - The second-hand housing market remains weak, with transaction volumes in major cities still negative compared to previous years [6] Agricultural Sector - The agricultural sector reported a revenue increase of 6.44% year-on-year for the first three quarters of 2025, but Q3 profits fell by 58.8% due to declining pig prices [35] - The pig farming sector is entering a de-stocking phase, while the feed and veterinary sectors are expected to improve as pig farming volumes recover [36] REITs Market - The REITs sector outperformed both stocks and bonds in the first half of 2025, with a total return of 13.41%, driven by policy support and demand resilience [42] - The second half of 2025 has seen a decline in REITs performance, highlighting a divergence in sector performance, particularly among consumption and logistics REITs [43] Computer Industry - The computer sector has shown a 25.12% increase year-to-date, with a low fund holding ratio of 2.92%, indicating potential for growth [46][47] - Key trends include rapid advancements in AI and domestic software and hardware, with significant opportunities for investment in AI applications and domestic technology [48] Wind Power Industry - The domestic wind power sector is expected to see significant growth, with a target of 120GW of new installations during the 14th Five-Year Plan period [51] - The industry is recovering from price wars, with improved bidding practices leading to better profitability for wind turbine manufacturers [52]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown significant growth in Q3, with a year-on-year increase in revenue and net profit, indicating strong performance and innovation potential [6][8] - The company is actively innovating in synthetic biology and other new fields, which may create new growth curves in the future [8] Financial Performance Summary - For the first three quarters of 2025, the company achieved revenue of 3.599 billion yuan, a year-on-year increase of 7.62%, and a net profit attributable to shareholders of 390 million yuan, a year-on-year increase of 661.66% [6] - In Q3 2025, the company reported a single-quarter revenue of 1.147 billion yuan, a year-on-year increase of 9.66%, and a net profit of 121 million yuan, a year-on-year increase of 522.30% [6] - The company has maintained high product prices, which has limited the decline in net profit compared to previous quarters [6][7] Product Performance Summary - The average price of the company's key product, Mancozeb, in Q3 2025 was 25,902 yuan/ton, with a year-on-year increase of 12.62% [7] - The average price of another key product, Bactericide, was 29,500 yuan/ton, reflecting a year-on-year increase of 47.42% [7] - The company benefits from its ownership of a 34% stake in a subsidiary, which contributes to its net profit growth due to rising product prices [7] Future Growth Potential - The company is focusing on advanced technologies such as RNAi biopesticides and small peptide biopesticides, which may lead to new product lines and revenue streams [8] - The establishment of the AI-driven platform is expected to enhance the efficiency of compound development and shorten the screening cycle for new compounds [8] Financial Projections - The company’s projected net profits for 2025, 2026, and 2027 are 503 million yuan, 575 million yuan, and 666 million yuan, respectively, with corresponding EPS of 1.13 yuan, 1.30 yuan, and 1.50 yuan [6][9] - The current stock price corresponds to a P/E ratio of 16.2, 14.2, and 12.3 for the years 2025, 2026, and 2027, respectively [6][9]

Core Viewpoint - Limin Co., Ltd. is a leading enterprise in the domestic fungicide industry, focusing on the research, production, and sales of agricultural fungicide raw materials and formulations, with a full industry chain and technological advantages [1] Group 1: Business Performance - In Q3 2025, Limin's operating revenue reached 3.599 billion yuan, ranking 11th in the industry, lower than the top competitor, Adama Agricultural Solutions, which reported 21.678 billion yuan [2] - The net profit for the same period was 411 million yuan, ranking 7th in the industry, below the leading company, Yangnong Chemical, which had a net profit of 1.056 billion yuan [2] - The main business composition includes agricultural fungicides at 1.24 billion yuan (50.57%), agricultural insecticides at 748 million yuan (30.51%), veterinary drugs at 229 million yuan (9.34%), and agricultural herbicides at 208 million yuan (8.47%) [2] Group 2: Financial Ratios - As of Q3 2025, Limin's debt-to-asset ratio was 45.34%, lower than the previous year's 60.02% and below the industry average of 46.06% [3] - The gross profit margin for Q3 2025 was 26.22%, an increase from 18.13% in the previous year and above the industry average of 21.70% [3] Group 3: Executive Compensation - The chairman, Li Xingsheng, received a salary of 1.8526 million yuan in 2024, an increase of 1.1307 million yuan from 2023 [4] - The president, Fan Zhaohui, earned 1.5071 million yuan in 2024, up by 682,200 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 7.91% to 55,500, while the average number of circulating A-shares held per household increased by 9.40% to 7,253.32 [5] - Analysts predict significant growth in net profit for 2025-2027, with estimates of 529 million yuan, 588 million yuan, and 648 million yuan respectively [5]